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Background: The mitogen-activated protein kinases (MAPKs) pathway is critical for cellular signaling, and proteins
such as phosphatases that regulate this pathway are important for normal tissue development. Based on our previous
work on dual specificity phosphatase-5 (DUSP5), and its role in embryonic vascular development and disease, we
hypothesized that mutations in DUSP5 will affect its function.
Results: In this study, we tested this hypothesis by generating full-length glutathione-S-transferase-tagged DUSP5
and serine 147 proline mutant (S147P) proteins from bacteria. Light scattering analysis, circular dichroism, enzymatic
assays and molecular modeling approaches have been performed to extensively characterize the protein form and
function. We demonstrate that both proteins are active and, interestingly, the S147P protein is hypoactive as compared
to the DUSP5 WT protein in two distinct biochemical substrate assays. Furthermore, due to the novel positioning of the
S147P mutation, we utilize computational modeling to reconstruct full-length DUSP5 and S147P to predict a possible
mechanism for the reduced activity of S147P.
Conclusion: Taken together, this is the first evidence of the generation and characterization of an active, full-length,
mutant DUSP5 protein which will facilitate future structure-function and drug development-based studies.
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The mitogen-activated protein kinases (MAPKs) pathways
are activated by dual phosphorylation of tyrosine and threo-
nine residues in their activation loops [1]. To regulate the
MAPKs, proteins that dephosphorylate at serine/threonine
and tyrosine residues have evolved. One class of phospha-
tases that dephosphorylate serine/threonine and tyrosine
residues is dual specificity phosphatases (DUSPs) [2]. Our
laboratory has previously identified one of the members
of the DUSP family, DUSP5, as critical for vascular* Correspondence: rramchan@mcw.edu
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unless otherwise stated.development and disease [3]. DUSP5 is well characterized
to specifically interact and dephosphorylate phosphorylated
extracellular regulated kinase (pERK), and does not act on
other MAP Kinases, such as p38 and JNK [2,4,5]. Also
unique to DUSP5 is that it localizes solely to the nucleus,
and its expression is induced by active pERK signaling [2].
Therefore, DUSP5 acts as a negative feedback loop on ac-
tive pERK signaling. It was also shown that DUSP5 is phos-
phorylated by pERK and can retain inactive ERK in the
nucleus, thus providing another layer of tight regulation [5].
Structurally, DUSP5 is predicted to have two globular do-
mains; an N-terminal ERK binding domain (EBD) and a C-
terminal phosphatase domain (PD) [2,6]. A crystal structure
of the DUSP5 PD [6] reveals a potential binding site for the
phosphate of pERK, which was occupied by anionic sulfate
groups. The PD domain is in part responsible for dephos-
phorylating pERK to ERK. Previously, we identified aThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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residue at the 147th position (S147P) in patients
afflicted with vascular anomalies [3]. Vascular anomalies
are inborn errors of developmental pathways, and are
classified broadly into two groups, namely vascular tumors
and vascular malformations. Vascular tumors such as
hemangiomas appear after birth, rapidly grow within the first
6 months, and suddenly involute, resulting in scarring and
other complications [7,8]. Vascular malformations, on the
other hand, are present at birth and are sustained throughout
the life of the individual, while affecting arteries, veins and
lymphatics. The identified S147P mutation, which is uniquely
located in the linker region adjoining the EBD, could poten-
tially interfere with the dephosphorylating activity of the
DUSP5 protein on its substrate pERK, and thus contribute
to the inception and progression of vascular anomalies.
Originally thought to be purely a structural motif, we
propose that the DUSP5 linker region plays an important
role in DUSP5 binding with pERK. To assess whether
S147P mutation has a consequence on DUSP5 activity,
we generated a glutathione-S-transferase (GST)-tagged
version of both wild type DUSP5 and mutant S147P
proteins. Here, using biochemical assays and computational
modeling, we have demonstrated that the S147P mutation
results in reduced DUSP5 activity and describe a potential
novel role for the linker region in pERK binding.
Methods
Cloning of GST-DUSP5 and GST-S147P constructs
The full-length wild type human DUSP5 cDNA was cloned
in a heterologous expression system as GST-DUSP5 fusion
protein using the PGEX-6P1 GST vector (GE Healthcare).
The cDNA was PCR amplified using Phusion High fidelity
DNA polymerase kit (F-530 L: Thermo Scientific). The PCR
was performed with Phusion GC buffer (F-519) containing
3% DMSO on a purchased cDNA template (Cat. #: EX-
Z2247-M49) from GeneCopoeia, Inc. USA. The primer se-
quences are: (hDUSP5-f: TTTGAATTCGCCACCATGA
AGGTCACGTCGCTC hDUSP5-r: TTTCTCGAGGCAGG
ATGTGGCCGTTGCCAC). The gel purified PCR product
was cloned in frame with GST in the pGEX-6P-1 vector at
the EcoRI and XhoI restriction sites. A single clone was se-
lected after sequencing for protein expression. Further, S147P
mutation was introduced in the wild type GST-DUSP5
plasmid by following the kit protocol as described in the
QuickChange Lightning Site-Directed Mutagenesis Kit
(Agilent Technologies, USA). The primer sequences are:
hDUSP5S147PF: GTGGATGTAAAACCCATTCCCCAAGA
GAAGATTGAGAGT, and hDUSP5S147P: ACTCTCAAT
CTTCTCTTGGGGAATGGGTTTTACATCCAC.
GST-DUSP5 and GST-S147P protein expression
GST-DUSP5 and S147P constructs were transformed into
Rosetta2 cells (Novagen, 71402–3). Pre-culture was startedwith picking a single colony from an overnight grown
plate. Ten mL of overnight culture was used to inoculate
1 L of terrific broth containing 10 mL of 40% glucose,
100 μg/ml carbenicillin and 34 μg/ml chloramphenicol.
The culture was grown at 37°C with shaking at 250 RPM.
When OD 600 reached 0.6, the culture was induced with
0.05 mM IPTG at 16°C for 20 h. The cells were then
harvested by centrifugation with 5000 RPM for 15 min
(Sorvall Super T21) at 4°C. The cell pellets were re-
suspended in a lysis buffer containing 50 mM Tris HCl
pH 8.0, 1% Triton X-100, 0.5 M NaCl, 10 mM EDTA,
10 mM EGTA, 10% glycerol, 2 mM PMSF, 5 mM DTT,
0.4 μg/ml Antipain and 0.2 μg/ml Leupeptin. The re-
suspended cells were sonicated (Misonix, Sonicator 3000),
and centrifuged at 10,000 RPM for 45 min (Sorvall) at 4°C.
GST pull down assay
GST-DUSP5 was absorbed to 10 μl glutathione beads with
shaking at 4°C for 2 h. After extensive washing, 20 μl of
SDS loading buffer was added into the resulting beads.
The mixture was heated for 3 min, loaded on 4-20% SDS-
PAGE gels, and stained with Coomassie blue.
GST-DUSP5 and GST-S147P protein purification
GST-DUSP5 and GST-S147P proteins were purified using
affinity chromatography. The cell extract of both recombin-
ant proteins were allowed to pass through pre-equilibrated
glutathione sepharose 4B beads twice. The column was
then washed thoroughly with lysis buffer and wash buf-
fer A50 (containing 50 mM Tris–HCl pH 7.5, 50 mM
NaCl, 5% glycerol and 1 mM DTT). The recombinant
proteins were then eluted using elution buffer (20 mM
glutathione + wash buffer, pH 7.5). The eluted protein
was concentrated using centrifugal filters (Amicon Ultra#
UFC905008, Eppendorf 5810R centrifuge).
PreScission protease cleavage of GST-DUSP5 and GST-S147P
GST was cleaved off the proteins using PreScission prote-
ase enzyme (GE Healthcare, 27-0843-01). For every 100 μg
of protein, 1 U of PreScission protease enzyme was used in
1x protease cleavage buffer containing 50 mM Tris HCl
pH 7.5, 150 mM NaCl, 1 mM DTT and 5% gycerol. The
mixture was incubated for 4 h at 4°C. The mixture was
then allowed to incubate with GST beads for 30 min, and
passed through the column. The resultant flow through
contains cleaved protein.
Dynamic light scattering
Dynamic Light Scattering (DLS) measurements at room
temperature were performed on DynaPro instrument
(Protein Solutions) with default parameters using a 12-μL
quartz cuvette. Data were acquired and processed with the
Dynamics (v5) software. Proteins (DUSP-5 at 1.5 mg/mL
and S147P at 1.8 mg/mL) in buffer (25 mM Tris.Hcl,
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trifuged at 13,000 rpm for 5 minutes prior to measurement.
CD spectroscopic verification of folded DUSP5
CD spectroscopy experiments were performed using a
Jasco J-710 spectropolarimeter. Protein solutions were
dialyzed into CD buffer containing 25 mM Tris–HCl
pH 7.5, 50 mM NaF, 1 mM TCEP, 5% glycerol, and 0.01%
IGEPAL. Protein concentrations used for CD were adjusted
to 0.2 mg/ml and then placed in a round cuvette with a
1 mm path length. Data were collected over a wavelength
range of 190–260 nm. At least five scans were acquired and
the averages were used for final analysis. CD spectra were
deconvoluted and secondary structure prediction obtained
using DICHROWEB [9] and the K2d algorithm [10].
Para-nitrophenol phosphate (pNPP) activity assay
Recombinant DUSP5 phosphatase activity was measured
using para-nitrophenol phosphate (pNPP) as a synthetic
substrate, and was performed as previously described [11]
with modifications. Assays were performed in 96-well
plates at a total volume of 200 μl. In brief, 1 μM of re-
combinant protein was added to assay buffer containing
100 mM Tris–HCl (pH 7.5), 100 mM NaCl, 5 mM MgCl2,
1 mM DTT, 0.5% Triton-X 100. The substrate, pNPP was
added last to the wells at the indicated concentrations
using a multichannel pipet. Absorbance was measured
every 30 seconds on a micro-plate reader (Molecular
Devices, SpectraMax, 340PC384) at 405 nm for 5 min, and
the ΔAbs/Δt were plotted on Michaelis-Menten graphs
with nonlinear regression best-fit curves using Prism 6.0
software (GraphPad Inc., San Diego, CA).
ERK dephosphorylation assay
To conduct this assay, 10 ng of GST-tagged recombinant
phosphorylated human ERK2 (R&D Systems, 1230-KS) was
incubated with and without the indicated DUSP5 proteins
(0.5 nM final concentration) for 5–15 min, as indicated.
The reactions were halted with 2x Laemmli sample buffer
and subjected to SDS-PAGE. The proteins were transferred
to polyvinylidene difluoride (PVDF) and immunoblotted
using antibodies to pERK (Cell Signaling Tech., #9106) and
total ERK (Cell Signaling Tech., #9102). Bound antibodies
were visualized using horseradish peroxidase-linked anti-
mouse IgG (Cell Signaling Tech, #7076S) and anti-rabbit
IgG (Cell Signaling Tech, #7074S), respectively, and ECL
reagents (Pierce, 34708) according to the manufacturer’s
protocol.
Homology modeling of EBD
The ERK-binding domain of human DUSP5 (i.e. residues
1–140) was constructed with the YASARA Structure
13.9.8 software [12,13] using the ‘hm_build’ macro (see
http://yasara.org/homologymodeling.htm for the detaileddescription of the homology modeling procedure). Inter-
estingly, the top ten structures produced by YASARA
were based on two templates, originating from the two
crystal structures (PDB codes: 2A2K [14] and 1YMD [15])
of human Cdc25B phosphatase catalytic domain (17% iden-
tity). Besides creating the template-based models, YASARA
also generated a hybrid model, in which it combines the
best features of the template-based models and thereby in-
creases the accuracy of resulting model beyond each of the
contributors. We refined the hybrid model as well as the
best template-based structures of EBD by performing
500-ps molecular dynamic simulations (see the details
of MD below) and found that the hybrid model has the
lowest energy. The credibility of this hybrid model, which
was used in subsequent modeling studies, was further so-
lidified by the fact that the most conserved residues were
localized on one face of EBD (Additional file 1: Figure S4),
as it is commonly found in various DUSPs [16,17]. It is
noted that the above fully automated homology modeling
procedure did not make use of the known structure of
EBD of DUSP6 from NMR studies (23% identity, PDB
code: 1HZM) [16]. To ensure the validity of our model,
we deliberately performed homology modeling using the
structure of EBD of DUSP6 and found that the resulting
structure had a low Z-Score value (−4.0; Z-Score < −2 can
be interpreted as poor, and < −4 as bad), when compared
to the Z-Score of the hybrid model (−0.1). The confidence
in our hybrid model was further ascertained by the Struc-
ture Analysis and Verification Server v4 (SAVES, see http://
services.mbi.ucla.edu) and PROtein Structure Evaluation
Suite and Server (PROSESS, see http://www.prosess.ca/)
[18], and details of the analysis are compiled in Additional
file 2: Figure S5.
Molecular dynamic simulations
The molecular dynamics simulations were performed using
Amber 03 force field [19] with a 7.86 Å force cutoff and
the Particle Mesh Ewald algorithm [20] to treat long-range
electrostatic interactions. A simulation cell was defined
to be cubic with periodic boundary conditions in all di-
rections, with a distance of at least 10 Å from protein
along each axis. The simulation box was filled with
TIP3P water [21] at density of 0.997 g/ml and Na/Cl ions,
which were placed at the lowest/highest electrostatic po-
tential locations to neutralize the cell and approximate the
physiological saline solution (0.9% NaCl). The protonation
states of acidic/basic amino acids were set according to
pH= 7.4. To remove bumps and correct the covalent
geometry, the structure was energy-minimized by a short
steepest descent minimization, followed by simulated an-
nealing (time step 2 fs, atom velocities scaled down by 0.9
every 10th step) until convergence was reached, i.e. the en-
ergy improved by less than 0.05 kJ/mol per atom during
200 steps. The obtained structure was used as a starting
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performed at T = 298 K with time step of 1.25 fs for
intramolecular interactions and 2.5 fs for intermolecular
interactions. Atomic velocities were rescaled using the
modified Broensted thermostat, based on time-averaged
temperatures, which does not depend on the strongly fluc-
tuating instantaneous microscopic temperatures [22].
Ethical considerations
This research does not involve human subjects, human
materials, or vertebrate animals. All experiments were
conducted under the Medical College of Wisconsin in-
stitutional safety approval.
Results
Optimization of conditions for DUSP5 protein expression
To generate full-length DUSP5 protein, our laboratory
used an E.coli expression strategy to express the full-length
human protein tagged with Glutathione-S-Transferase
(GST), which enhances solubility of the protein. Previ-
ous attempt at generating soluble protein with histidine
tag was not successful (data not shown). Generation of
full length active and mutant DUSP5 proteins will greatly
assist structural studies and the ability to discern the
mechanism of action of these proteins in the progression
of vascular anomalies. The full-length human DUSP5 was
cloned into a pGEX-6P1 vector (Figure 1A) and DNA se-
quencing was performed to confirm the DUSP5 sequence.
We transformed pGEX-6P1-DUSP5 into Rosetta 2 cells.
Initially, temperature and IPTG concentrations were em-
pirically optimized. Bacteria growth was tested in lysogeny
broth (LB) under two different temperature conditions of
16°C and 25°C (Figure 1B). Under each condition we per-
formed + and – IPTG (0.2 mM) for comparison purposes
and lysed cells by sonication to separate the soluble and
insoluble components as described in the materials and
methods section. DUSP5 protein was observed by Coo-
massie staining but, unfortunately, the DUSP5 protein
band was again observed in the insoluble cell pellet
(Figure 1C). We next varied the IPTG concentrations
using 0.01 mM and 0.05 mM, while maintaining the
16°C and 25°C temperature conditions. We detected
the DUSP5 protein at 16°C, 0.05 mM IPTG, and over-
night induction condition (Figure 1D). However, the
protein was still observed in the insoluble cell pellet
(Figure 1E). We next switched the media from LB to
terrific broth (TB), and the expression was carried out
at 16°C using an overnight induction with 0.05 mM
and 0.1 mM IPTG concentration (Figure 1F). We ob-
served a GST-DUSP5 protein band at the correct size
in the soluble fraction when induced with at 16°C with
0.05 mM and 0.1 mM IPTG (Figure 1G, lanes 3 and 6).
However, the protein was less soluble in the 0.1 mM IPTG
condition as demonstrated by the presences of a strongprotein band in pellet fraction (Figure 1G, lane 5). Based
on the testing of various parameters, we concluded that
TB media with 0.05 mM IPTG at 16°C was the best condi-
tion for generating soluble GST-DUSP5 protein.
GST-DUSP5 protein purification
Based on conditions described earlier, we generated 1 L
culture of bacteria, and induced it with IPTG accordingly.
The E.coli cells were harvested, and the bacterial pellet
was resuspended in lysis buffer containing 1% Triton
X-100. The soluble protein was collected by sonication
followed by centrifugation. Purification of cell extract
was carried out using glutathione sepharose 4B affinity
chromatography. As shown in Figure 1G, lane 4, the ma-
jority of the protein bound to the glutathione-sepharose
beads. To elute the bound protein, 20 mM reduced gluta-
thione in buffer A50 was used. A single band of 68 kDa
was observed in the Coomassie gel (Figure 2A). Free gluta-
thione was removed by repeated steps of concentration of
eluate followed by dilution in buffer A50. The final protein
yield for 1 L cell culture was 7.8 mg. To remove the GST
tag, we performed a PreScission protease cleavage reaction
that recognizes the PreScission protease cleavage site em-
bedded between the GST tag and DUSP5. Following the
protease cleavage, a single band of 37 kDa was observed in
the Coomassie gel (Figure 2B). Using similar methods to
wild type DUSP5, we also expressed, induced and purified
GST-S147P protein as shown in figures 2C and D. Taken
together, we have successfully expressed, purified, and
cleaved the GST tag to generate pure untagged DUSP5
and S147P proteins.
DUSP5 protein characterization
To further characterize the proteins, we performed mass
spectrometry (LC-MS/MS), dynamic light scattering (DLS),
and circular dichroism (CD) analysis. The LC-MS/MS ana-
lysis identified peptides corresponding to 35.7% of both
DUSP5 and S147P, with 99.7% coverage over the entire pro-
tein sequence (Figure 3A and Additional file 3: Figure S1).
To test for proper folding of our proteins we utilized CD
along with DICHROWEB to estimate secondary structure
(Figure 3B and Additional file 4: figure S2). Our CD results
indicated that cleaved DUSP5 contained 43% alpha helix
and 20% beta sheet. This data tightly correlates with our
predicted structure model of DUSP5 (described later)
which contains 40.9% alpha helix and 15.6% beta sheet.
Additionally, these results correlate to previously reported
CD spectra from DUSP6 [23] and similar results were
obtained for all DUSP5 constructs. Thus, these results
confirm the identity of the purified, cleaved DUSP5 and
S147P recombinant proteins and indicate proper folding.
We next performed DLS, which measures fluctuations
in scattering intensities emanating from particles that
undergo random Brownian motion. Diffusion coefficient
Figure 1 Construction of plasmid and Optimization of expression condition. (A) pGEX-6P-1 vector map. (B-C) Effect of temperature on GST-DUSP5
protein expression. (B) Lane 1: MW marker, lanes 2, 4, 6 and 8: cell pellet before induction, lanes 3, 5, 7 and 9: cell pellet after induction. Lanes 2–3, 4–5
are induced at 25°C for 20 h, lanes 6–7, 8–9 are induced at 16°C for 20 h. Lanes 4–5 and 8–9 are duplicate samples for lanes 2–3 and 4–5 respectively. (C)
Effect of temperature on GST-DUSP5 solubility, Lane 1: MW marker, lanes 2 & 4 and 3 & 5 are cell pellet, and cell lysate post sonication, and samples
induced at 25°C overnight for 20 h, lanes 6 & 8 and 7 & 9 are cell pellet and cell lysate post sonication, and samples induced at 16°C overnight for 20 h.
(D-E) Effect of IPTG concentration on GST-DUSP5 protein expression. (D) Lane 1: MW marker, lanes 2, 4, 6 & 8: cell pellet before induction, and lanes 3, 5,
7 & 9: cell pellet after induction either with 0.01 mM or 0.05 mM IPTG at 25°C or 16°C for 20 h. (E) Effect of IPTG concentration on GST-DUSP5 solubility.
Lane 1: MW marker, lanes 2, 4, 6 & 8 cell pellet post sonication, and lanes 3, 5, 7 & 9 are cell lysate post sonication for expression induced with either
0.01 mM or 0.05 mM IPTG, at 25°C or 16°C. (F) GST-DUSP5 protein expression using terrific broth and 0.05 mM and 0.1 mM IPTG and 16°C
overnight induction. Lane 1: MW marker, lanes 2 & 4 and 3 & 5 are cell pellet before and after induction. Lanes 2–3: 0.05 mM IPTG, lanes 4–5:
0.1 mM IPTG. (G) GST-DUSP5 protein solubility and GST pull down. Lane 1: MW marker, lanes 2 & 5 are cell pellet post sonication, lanes 3 & 6
are cell lysate post sonication, lanes 4 & 7 are protein adsorbed on GST beads.
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Figure 2 GST-DUSP5 and GST-S147P Proteins Purification. (A) GST-DUSP5 protein purification. Lane 1: MW marker, lane 2: cell lysate, lane 3: GST
pull down (GST-DUSP5 was adsorbed on glutathione sepharose 4B and loaded on gel), lanes 4–7 purified GST-DUSP5 protein fractions. (B) GST-DUSP5
PreScission protease cleavage. Lane 1: MW marker, lane 2: Purified GST-DUSP5, lanes 3–6: GST-DUSP5 protein eluted following PreScission
protease digestion. (C) GST-S147P protein purification. Lane 1: MW marker, lane 2: cell lysate, lane 3: GST pull down (GST-S147P was adsorbed on
glutathione sepharose 4B and loaded on gel), lanes 4–7 purified GST-S147P protein fractions. (D) GST-S147P PreScission protease cleavage.
Lane 1: MW marker, lane 2: purified GST-S147P, lane 3–6: protein eluted following PreScission protease digestion.
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are determined from analyzing these fluctuations. When
DLS was performed on both wild type DUSP5 and S147P
proteins in solution, we observed trace amounts of very
large molecular weight species (Rh > 30 nm) (Figure 3C
and Additional file 5: figure S3). The main protein peak is
spread around 5 nm, and the polydispersity varies as well.
The estimated Rh range for DUSP-5: 3.6 to 6.0; average
(n = 7) Rh = 4.8 nm which corresponds to a MW of
132 kDa. For S147, the estimated Rh ranged from 3.3 to
5.3; average (of seven measurements) Rh = 4.5 nm which
corresponds to a MW of 114 kDa. The predicted molecu-
lar weight of the protein is 42 kDa, and DUSP5 protein in
a dimer configuration would be 84 kDa. A typical Rh value
of 4.0 nm would correspond to about 86 kDa. Because the
crystal structure of the C-terminal phosphatase domain is
reported to form a dimer (PDB code, 2g6z), we investi-
gated whether disulfide formation between cysteine res-
idues in the proteins would contribute to this dimer
formation and accordingly activity of these proteins.
Addition of DTT showed a clear increase in the phos-
phatase activity of the WT DUSP5 protein (Figure 3D).
The DLS results and the DTT results point to possible
association of protomers, likely dimers, being the dom-
inant species in solution for both wild type and S147P
proteins, as well as sensitivity to reducing environments.
Taking the protein characterization data together, we have
successfully generated full-length, soluble, folded versionsof both GST-DUSP5 and GST-S147P proteins and their
cleaved counterparts from bacteria.
Activity of GST-tagged and untagged DUSP5 proteins
To determine the activity of GST-tagged proteins, we per-
formed para-nitrophenol phosphate (pNPP) activity assay
(Figure 4). In this assay, 1 μM of recombinant DUSP5 pro-
teins was added to assay buffer, and the substrate, pNPP,
was added last to the wells at the indicated concentrations.
Absorbance was measured at 405 nm every 30 seconds for
5 min, and the ΔAbs/Δt used to calculate initial velocities,
which were then plotted as Michaelis-Menten curves and
fitted (nonlinear least squares regression). As expected,
the GST protein had no activity in this assay. Interestingly,
the mutant exhibited a 2-fold decrease in Vmax when com-
pared to the wild type DUSP5 protein. The GST-S147P
exhibited Vmax = 0.27 ± 0.01 nmol/min and Km = 2.3 ±
0.56 mM, while GST-DUSP5 exhibited Vmax = 0.63 ±
0.03 nmol/min and Km = 5.23 ± 1.0 mM (Figure 4A and
Table 1). We also obtained a His-tagged DUSP5-PD
domain-only protein from our collaborators, which was
similar to the one crystallized by Jeong et al. [6], and in-
vestigated its activity in the pNPP assay in comparison
to the two full-length DUSP5 proteins. Interestingly,
the PD alone had lower Vmax (0.06 ± 0.003 nmol/min)
and Km (1.7 ± 0.45 mM) than GST-DUSP5 or GST-S147P
full-length proteins, implying that the EBD domain is im-
portant for DUSP5’s activity (Table 1). We next investigated
Figure 3 Protein characterization. (A) Mass spectrometric analysis was performed by Bioproximity, LLC on coomassie identified bands of the
appropriate size separated by SDS-PAGE. Samples were subjected to in-gel trypsin digestion and the peptides recovered for mass spectrometric
analysis. (B) Circular dichroism was performed to determine folding and secondary structure of DUSP5, which was found to be 43% alpha helical
and 20% beta-sheet. (C) Dynamic Light Scattering predicts oligomerization of both DUSP5 and S147P. (D & E) GST-DUSP5 is active and sensitive
to the addition of DTT. Specifically, 1 mM DTT increased the activity of GST-DUSP5 against pERK2 in vitro.
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its GST tag (Figure 4B). The cleaved WT DUSP5 shows
lower Vmax = 0.36 ± 0.03 nmol/min and Km = 3.0 ± 1.0 mM
compared to GST-DUSP5, and similarly cleaved S147P
shows lower Vmax = 0.13 ± 0.01 nmol/min and Km = 1.3 ±
0.55 mM compared to GST-S147P (Figure 4B and Table 1).
However, the trend of S147P showing decreased activity
compared to DUSP5 is consistent for both cleaved and
uncleaved proteins. These results collectively suggest that
mutant S147P protein is less active than wild type DUSP5
protein and that both EBD and PD domains are necessary
for full activity of DUSP5.Activity of the mutant S147P and WT DUSP5 to pERK
We complemented the pNPP assay with a second assay
using the natural substrate of DUSP5, pERK2 (Figure 5).
In this assay, GST-DUSP5 and GST-S147P (0.5 nM) are
incubated in the presence of purified pERK2 (10 nM) for
5 or 15 min, and dephosphorylation determined by western
blot. As shown in Figure 5A, incubation with GST-DUSP5
protein decreases pERK levels more than GST-S147P at
both time points indicating hypoactivity of S147P to its
natural substrate, pERK, and corroborating the hypoac-
tivity of S147P observed in the pNPP activity assay.
We also performed a titration curve with different doses
Figure 4 GST-DUSP5 and GST-S147P proteins are active against pNPP in vitro. Panels (A-B) are Michaelis-Menten curves derived from pNPP
assays performed with recombinant proteins. (A) Michaelis-Menten curves with GST, GST-DUSP5 and GST-S147P proteins. (B) Michaelis-Menten curves
with cleaved versions of S147P and DUSP5 proteins.
Table 1 Michaelis-Menten parameters (Non-linear least
squares regression)
M-M Kinetics GST-DUSP5 GST-S147P GST DUSP5-PD
Vmax
(nmol/min)
0.63 ± 0.03 0.27 ± 0.01 NA 0.06 ± 0.01
Km (mM) 5.24 ± 1.0 2.33 ± 0.56 NA 1.7 ± 0.45
M-M Kinetics DUSP5 (cleaved) S147P (cleaved)
Vmax
(nmol/min)
0.36 ± 0.03 0.13 ± 0.01
Km (mM) 3.0 ± 1.0 1.3 ± 0.55
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the pERK assay (Figure 5B). At 0.5 nM concentration of
GST-DUSP5, the pERK band is completely absent, and
the comparable concentration for the same effect for
GST-S147P is 5 nM, a ten-fold higher concentration
(Figure 5B). Again, these data along with the pNPP assay
data suggest that S147P is less active than WT DUSP5
protein.
Modeling studies
To further explain the mechanism of the hypoactivity of
mutant S147P protein, we performed computational mod-
eling studies. The complete model of DUSP5/pERK2 was
built using two domains of DUSP5, i.e. ERK-binding do-
main (EBD) and phosphatase domain (PD), and phosphor-
ylated ERK2. The structure of PD was available from
the X-ray crystallography [6], while the structure of EBD
was obtained by homology modeling (see Experimen-
tal Procedures section). The crystal structure of non-
phosphorylated ERK2 [24] was modified by insertion
of the phosphate groups in the Thr185 and Tyr187 resi-
dues, and it was refined by a long (8 ns) molecular dynamic
simulation, during which the phosphorylated threonine
(TPO) and tyrosine (PTR) residues adopted conformations
similar to those reported for rat pERK2 [1] (Additional
file 6: Figure S6).
The initial assembly of PD with pERK2 was guided by
the fact that the X-ray structure of PD contained twosulfate ions, which were separated by ~7 Å [6], and
therefore it was surmised that the phosphate groups of
TPO185 and PTR187 of pERK2 occupy these same sites
in the complex of PD with pERK2. Indeed, a juxtapos-
ition of these domains using the YASARA software [13]
resulted in a structure, in which the phosphate group of
PTR187 penetrated deep inside the binding site of the
active center of PD, and stability of the PD/pERK2 com-
plex was confirmed by 8-ns MD simulations. Next, the
Z-Dock protein-protein docking server [25] was utilized
to juxtapose EBD to pERK2 while only taking into account
the proximity of the kinase interaction motif of EBD
(52LRR54) [5] and common docking motif (318DPSD321) of
pERK2 [26]. The resulting structure showed not only the
interaction between the requested motifs but also pre-
dicted interactions of a hydrophobic groove near the
Figure 5 GST-DUSP5 and GST-S147P proteins are active against
pERK in vitro. Panels (A-B) are p-ERK western blots performed with
purified WT DUSP5 or S147P proteins. (A) Time course experiment
with 5 min and 15 min incubation of DUSP5 recombinant proteins
with pERK. (B) Dose curve of recombinant DUSP5 proteins with a
15 min incubation period with pERK.
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phobic segment of EBD (59AVSA62), which is likely to
be important for the specificity of DUSP5 towards ERK
[26]. Furthermore, our confidence in the model was sup-
ported by the fact that the position of EBD in the predicted
structure matches a large spot of highly conserved residues
on the back face of pERK2 (Additional file 7: Figure S7).
The resulting structure of the EBD/pERK2/PD complex
was refined by a 500 ps-long MD simulation.
Next, we connected the C-terminus of the EBD to the
N-terminus of the PD in the EBD/pERK2/PD complex by
the linker, which consists of ~40 amino acids (Figure 6A
and A’). The position of the N-terminus of the linker cor-
responds to one end of a deep and long groove on top of
the N-domain of pERK2, which suggests a possible path-
way around pERK2. Indeed, after arranging the linker in
the groove on the surface of N-domain of pERK2 and re-
fining the structure by an 8-ns MD simulation (Figure 6A
and A’), we found that the linker not only spans the
needed length but is also involved in a number of favor-
able interactions with pERK2 (e.g. the interacting pairs
of residues of DUSP5 and pERK2: Ile146–Val46, Glu154–
Gln97, Arg155–Asp20, Ser159–Asp100), which facilitate
effective binding.
Based on this model, we propose the following scenario
of DUSP5 binding to pERK2. First, EBD binds to the C-
domain of pERK2, which brings the N-terminal side of the
DUSP5 linker to the beginning of the groove on top of theN-domain of pERK2 (Figure 6B). Next, the linker arranges
itself in this groove in a zipper-like action, thereby bring-
ing PD to the phosphorylated residues of pERK2. Finally,
the two anion-binding sites of PD recognize the phosphor-
ylated threonine and tyrosine residues of pERK2 that are
present in the pThr-Glu-pTyr region of its activation loop,
directing insertion of PTR187 into the active site of
DUSP5 (Figure 6C), where the trans-phosphorylation
or dephosphorylation reaction occurs.
To analyze the effect of the S147P mutation, we swapped
Ser147 to proline in the model of the DUSP5/pERK2
complex, and performed an 8-ns molecular dynamic
simulation. Analysis of the MD trajectories showed that
the mutation leads to structural rearrangement in DUSP5,
which involves displacement of the EBD and N-terminal
side of the linker away from the N-domain of pERK2
(Additional file 8: Figure S8). These distortions indicate
that mutation of Ser147 to proline in the DUSP5 leads
to an altered arrangement of the linker in the groove of
pERK2. Thus, we suggest that the observed reduction
in the catalytic activity of the mutant S147P originates
because of deviation from the optimal binding of the
EBD-PD linker to pERK2, thereby resulting in a slower
formation of pre-reaction complex and slower rate. In-
deed, based on the cursory examination it is expected
that the conformational changes in the linker arising
from serine-to-proline mutation should alter the optimal
arrangement of the linker in the binding groove of pERK2
(Figure 6D and E). Collectively, the molecular simulation
studies provide a molecular explanation for the decreased
activity of S147P towards pERK when compared to wild
type DUSP5 protein.
Discussion
This study defines and describes the generation of an
active protein of clinical relevance, namely DUSP5, in
milligram amounts that allows for future structure-
function based studies. Importantly, we describe the sol-
uble production of full length GST-tagged DUSP5 and
mutant S147P proteins that are active. We also demon-
strate that the S147P protein is less active than wild type
DUSP5 in its activity towards two distinct substrates and
that the two domains of DUSP5 are critical for its full
functional activity. Lastly, we provide for the first time a
computational structure analysis of the ERK-DUSP5 inter-
action, from which we identify a potential active role of
the DUSP5 linker region in ERK binding. Our structural
analysis also reveals a potential mechanism to the reduced
activity of the S147P protein.
Previously, DUSP5 protein has been crystallized, and
the source of this protein was from E.coli [6]. However,
this crystal structure was determined from the PD alone,
and the authors also included a mutation Cys263Ser, which
was likely necessary to obtain well-diffracting crystals. We
Figure 6 Computational modeling of human pERK2 and DUSP5 proteins. Panels (A and A’) are computational model of human pERK2
with DUSP5 protein complex from different points of view (pERK2 is shown in surface representation). Panel (B) represents the binding interface
between EBD and pERK2, which consists of kinase interaction motif (KIM) of EBD and common docking motif (CD) of pERK2, as well as of
hydrophobic 59AVSA62 sequence of EBD and hydrophobic groove of pERK2. Panel (C) represents the interaction of activation segment of
pERK2 (TPO185-Glu-PTR187) with the active site of DUSP5. Panels (C and D) are schematic representation of the effect of serine-to-proline
mutation on the DUSP5/pERK2 complex.
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conformation of DUSP5 and mutant DUSP5, milligram
amounts of the proteins was needed in a soluble form.
We utilized GST to tag DUSP5, since GST is known to fa-
cilitate the folding and solubility of proteins [27]. GST-
DUSP5 protein clearly was soluble, and our yields rou-
tinely ranged in the 5–10 mgs per liter concentration of
bacterial culture thereby suggesting that future struc-
ture studies are feasible with scale-up. Due to the bulky
nature of GST (26 kDa) in relation to the DUSP5 pro-
tein size (42 kDa), we cleaved the GST off the DUSP5
using PreScission protease. This introduced two issues:(a) multiple bands were observed on PreScission cleavage,
and (b) the yield dropped significantly. We sequenced the
bands resulting from the PreScission cleavage reactions,
and confirmed that one of the bands was indeed cleaved
DUSP5 protein. Although yields are low, we can scale-up
the cultures to overcome this limitation of the cleaved
protein. Because the crystal structure of the C-terminal
PD is a dimer (PDB code, 2g6z) [6], it is plausible that
the C-terminal PD domain of the full length protein do
interact to form a dimer in solution. Based on the DLS
data, if there is any interaction between the N-terminal
domains, the hydrodynamic radius (Rh) could be higher
Nayak et al. BMC Biochemistry  (2014) 15:27 Page 11 of 13than expected for a “strict” dimer. Rh would be less if
both N- and C- domains of two protomers interact with
the respective partners. Conversely, Rh would be high if
only the C-terminal domains form dimeric interaction
while the N-terminal domains are only coming along
because they are attached. In either scenario, the pro-
pensity of DUSP5 to form oligomers is a property that
appears to be functionally relevant since breaking disul-
fide bonds with DTT, and thus presumably creating
single, monomeric species, altered enzymatic activity
of the protein. Whether the mutation in DUSP5 has a
propensity to oligomerize is a question that needs fur-
ther investigation.
pERK2, the natural substrate for DUSP5, is well estab-
lished in its role in endothelial cell proliferation [28].
The present model for binding [29] has the two domains
(EBD & PD) of DUSP5 enveloping pERK2 on opposite
faces as shown in Figure 6A/A’ in a tweezer-like action.
Based on analogy to other MAP kinase phosphatases [29],
we expect that the EBD and PD domains of DUSP5 bind
ERK cooperatively, such that the previously reported ERK
binding motif in the EBD [29] (52LRR54, Figure 6B)
interact with the common docking motif (318DPSD321)
of pERK2 (Figure 6B), and the hydrophobic segment in
EBD (59AVSA62) interacts with the hydrophobic groove of
pERK2, as shown on Figure 6B. Previously, Camps et al.
[30] demonstrated that ERK binding to the non-catalytic
amino-terminal domain of MKP3 dramatically activates
the phosphatase catalytic domain. Structural and physical
evidence suggests that ERK activates MKP3 through the
stabilization of the active phosphatase conformation, in-
ducing closure of the catalytic “general acid” loop [31]. In
this closed conformation, the loop structure can participate
efficiently in general acid/base catalysis, substrate binding,
and transition-state stabilization. However, catalytic activity
of DUSP5 PD does not seem to require activation through
binding of its substrate, pERK [5,6], and therefore the in-
hibition observed due to S147P mutation must arise from
the structural rearrangement of the EBD–PD linker in the
DUSP5/pERK2 complex. Based on our molecular model-
ing studies, the linker in the WT DUSP5/pERK2 complex
is aligned in the groove on top of the N-terminal domain
of pERK2 (Figure 6A/A’). The S147P mutation disrupts the
optimal alignment of the linker in the pERK2 groove due
to the dramatic conformational change (Figure 6D/E) and
thus results in a slower formation of the pre-reaction
complex and reduced catalytic activity of S147P mu-
tant. Deviation from the optimal binding of DUSP5 to
pERK could result into following consequences. First,
the S147P mutation can destabilize a pre-reactive com-
plex to facilitate its dissociation to the non-interacting
DUSP5 and pERK, which would lead to a further reduction
in the overall reaction rate. Second, the S147P mutation
can as well facilitate decomposition of the post-reactioncomplex. We believe that the latter process is not a rate-
limiting reaction step either in WT or mutant DUSP5
complex, which is in agreement with the recent theoretical
study of trans-phosphorylation in Cdc25 [32], and there-
fore it should not affect the overall reaction rate. However,
we plan to address this question in greater detail in our
future planned theoretical study.
We recreated the previously identified S147P mutation
in patients with vascular anomalies [3] in the GST-DUSP5
template, and successfully generated milligram amounts of
soluble S147P protein. Until now, it was not known
whether this mutation was a gain- or loss-of-function.
Our assays here imply that S147P is a loss-of-function
mutation in that it dephosphorylates residues in pNPP
or pERK at a slower rate than wild type DUSP5 protein;
however, the physiological relevance of this drop in ac-
tivity in vitro remains to be determined. If this muta-
tion is partially responsible for the natural history of
vascular anomalies, it implies that the loss-of-function
mutation is likely to slow the removal of phosphates
from active pERK. Since ERK activity is often correlated
with the cells ability to proliferate, such as the case in
cancer [33,34], the endothelial or vascular progenitor cell
that contains the causative DUSP5 somatic mutation is
likely to lose the ability to negatively regulate pERK, thus
causing endothelial cell to hyperproliferate, and display
the vascular anomaly phenotype. Besides vascular anomal-
ies, DUSP5 has also been implicated as a target for cardiac
hypertrophy and immune conditions. Recent data suggests
that small molecule histone deacetylase (HDAC) inhibi-
tors suppress cardiac hypertrophy via inhibition of DUSP5
[35]. Cardiomyocytes, the primary cell type involved in
cardiac hypertrophy, show differential effects on ERK
signaling in the nucleus and cytoplasm; in that nuclear
ERK1/2 activation is suppressed in a DUSP5-dependent
manner, while cytosolic ERK1/2 activation is maintained
under these same conditions [35]. In regards to the role of
DUSP5 in immunology, DUSP5 expression is induced by
IL-2 stimulation and regulates B-cell differentiation [36].
Additionally, overexpression of human DUSP5 in mice re-
sults in an autoimmune phenotype, as well as increased
proliferation of activated memory T-cells [37]. Therefore,
finding small molecule that selectively activate or inhibit
DUSP5 in a context-dependent manner is important, and
is the focus of studies in our laboratories.
Conclusions
DUSP5 has been shown to be a critical protein involved
in several disease phenotypes. Therefore, to better under-
stand the structure-function relationship of DUSP5, we
generated and characterized both wild-type and mutant
DUSP5 while providing a comprehensive molecular model
of the DUSP5/ERK interaction. In addition to showing
decreased activity of the mutant DUSP5, our molecular
Nayak et al. BMC Biochemistry  (2014) 15:27 Page 12 of 13model revealed a novel role for the DUSP5 linker region
in DUSP5/ERK interactions. Taken together, our studies
will allow for the identification of activators or inhibitors
of DUSP5; as well as the selective modulation of S147P’s
activity rather than wild type DUSP5 activity – a concept
that is the hallmark of targeted drug discovery approaches.Availability of supporting data
The data sets supporting the results of this article are
included within the article and its additional files.Additional files
Additional file 1: Figure S4. Molecular modeling of DUSP5 EBD. The
molecular surface (left side) and cartoon & sticks representation (right side)
of the hybrid model of DUSP5 EBD colored by the residue conservation
scores obtained from the ConSurf Server [38] (web address: consurf.tau.ac.il).
Cyan color corresponds to most variable residues, violet color—to the most
conserved ones.
Additional file 2: Figure S5 Homology model validation. Validation of
the homology model based on the 1HZM template (top) and the hybrid
model (bottom) by the SAVES server (left side) and PROSESS server (right side).
Please visit http://services.mbi.ucla.edu/SAVES/T/?job=16119 and http://
services.mbi.ucla.edu/SAVES/T/?job=16120 for the full HTML reports from
the SAVES server.
Additional file 3: Figure S1. Mass spectrometry of mutant DUSP5. The
cleaved, purified mutant DUSP5 (S147P) was sent to Bioproximity for mass
spectrometric protein identification. Mass spectrometric analysis was
performed on Coomassie identified bands of the appropriate size separated
by SDS-PAGE. Samples were subjected to in-gel trypsin digestion and the
peptides recovered for mass spectrometric analysis, LC-MS/MS. Mass
spectrometric analysis performed on the peptide fragments identified
35.7% of the DUSP5 sequence (bold), with 99.7% coverage over the
entire protein sequence for both WT DUSP5 and S147P.
Additional file 4: Figure S2. Circular dichroism data with WT DUSP5
and mutant constructs. Folding and secondary structure composition of
the recombinant DUSP5 constructs was assessed by circular dichroism
(CD). The spectra were deconvoluted using DICHROWEB. Secondary
structure determinations were as follows: GST-DUSP5 34% α-helix and
19% β-sheet; GST-S147P 31% α-helix and 11% β-sheet; DUSP5 43% α-helix
and 20% β-sheet; S147P 58% α-helix and 8% β-sheet. The normalized
root-mean-square deviations (NRMSD) were less than 0.1 for all constructs.
Additional file 5 Figure S3. Dynamic Light Scattering of S147P. When
DLS was performed on both native DUSP-5 and S147P proteins in solution,
we observed trace amounts of very large molecular weight species (Rh >
30 nm). For S147, the estimated Rh ranged from 3.3 to 5.3; average (of seven
measurements) Rh = 4.5 nm which corresponds to a MW of 114 kDa. This
data indicates that S147P, normally 42 kDa, may dimerize in solution.
Additional file 6: Figure S6. Phosphorylated ERK2 modeling. Top:
structure of human pERK2 after manual addition of phosphate groups
and 500-ps molecular dynamic refinement. Bottom: crystal structure of
rat pERK2 (PDB: 2ERK [1]).
Additional file 7: Figure S7. ERK2 molecular surface. The molecular
surface of ERK2 (PDB code: 2OJG [24]) colored by the residue conservation
scores obtained from the ConSurf Server [38] (web address: consurf.tau.ac.il).
Cyan color corresponds to most variable residues, violet color—to the most
conserved ones. Encircled is the sulfate anion found in the X-ray structure of
dephosphorylated ERK. The conserved residues on the left panel are
responsible for the kinase activity of pERK2 as well as interactions with
phosphatase domains of DUSPs (N-domain of pERK2 is on the upper
side of the figure, while N-domain – on the lower side). Compact
localization of conserved residues on the rear side of pERK2 (left panel)
presumably denotes interface for binding with EBDs.Additional file 8: Figure S8. Juxtaposed model structures of WT and
mutant DUSP5. The molecular representation of the juxtaposed model
structures of WT (blue color) and S147P mutant (green color) DUSP5.
Blue/green ellipses denote orientation of individual domains. Yellow
rectangle highlights structural displacement near the N-side of the EBD-PD
linker; curved yellow arrow denotes arrangement of the resting part of the
linker.
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